Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REV1 | Q9UBZ9 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403077 | 0.92 | REV1 (0.53) | REV1LMNAMAPTHTTMEN1 | |
| SCHEMBL1109346 | 0.91 | TSHR (0.57) | REV1LMNAMAPTHTTMEN1 | |
| SCHEMBL10287218 | 0.86 | ALDH1A1 (0.56) | REV1LMNAMAPTHTTMEN1 | |
| SCHEMBL1109284 | 0.86 | LMNA (0.47) | LMNAMEN1KMT2AGAA | |
| SCHEMBL1109453 | 0.86 | NPC1 (0.54) | LMNAHTTMEN1KMT2ATDP1 | |
| SCHEMBL1109217 | 0.85 | ATM (0.50) | LMNAALOX15 | |
| SCHEMBL1109357 | 0.85 | NPC1 (0.53) | MAPTHTTMEN1KMT2ATDP1 | |
| SCHEMBL1109198 | 0.85 | NPC1 (0.53) | MAPTHTTMEN1KMT2ATDP1 | |
| SCHEMBL1109382 | 0.85 | LMNA (0.56) | REV1LMNAMAPTHTTMEN1 | |
| SCHEMBL1109318 | 0.84 | ALDH1A1 (0.49) | MEN1KMT2ATDP1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | REV1 293/4885LMNA 3397/4885MAPT 4619/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | REV1 293/4885LMNA 3397/4885MAPT 4619/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | REV1 293/4885LMNA 3397/4885MAPT 4619/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | REV1 293/4885LMNA 3397/4885MAPT 4619/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | REV1 293/4885LMNA 3397/4885MAPT 4619/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | REV1 293/4885LMNA 3397/4885MAPT 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.